ES2390879T3 - Formulaciones de atomoxetina - Google Patents

Formulaciones de atomoxetina Download PDF

Info

Publication number
ES2390879T3
ES2390879T3 ES04815693T ES04815693T ES2390879T3 ES 2390879 T3 ES2390879 T3 ES 2390879T3 ES 04815693 T ES04815693 T ES 04815693T ES 04815693 T ES04815693 T ES 04815693T ES 2390879 T3 ES2390879 T3 ES 2390879T3
Authority
ES
Spain
Prior art keywords
atomoxetine
dosage form
coating
composition
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04815693T
Other languages
English (en)
Spanish (es)
Inventor
Garth Boehm
Josephine Dundon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Group PTC ehf
Original Assignee
Actavis Group PTC ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actavis Group PTC ehf filed Critical Actavis Group PTC ehf
Application granted granted Critical
Publication of ES2390879T3 publication Critical patent/ES2390879T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES04815693T 2003-12-31 2004-12-23 Formulaciones de atomoxetina Expired - Lifetime ES2390879T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53351703P 2003-12-31 2003-12-31
US533517P 2003-12-31
PCT/US2004/043678 WO2005065673A1 (en) 2003-12-31 2004-12-23 Atomoxetine formulations

Publications (1)

Publication Number Publication Date
ES2390879T3 true ES2390879T3 (es) 2012-11-19

Family

ID=34748912

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04815693T Expired - Lifetime ES2390879T3 (es) 2003-12-31 2004-12-23 Formulaciones de atomoxetina

Country Status (7)

Country Link
US (1) US20050152974A1 (https=)
EP (1) EP1715856B1 (https=)
JP (1) JP2007517050A (https=)
AU (1) AU2004312059A1 (https=)
CA (1) CA2552064A1 (https=)
ES (1) ES2390879T3 (https=)
WO (1) WO2005065673A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
US20080153808A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
JP2012513475A (ja) * 2008-12-23 2012-06-14 レヴァイン，ジョシュア・ディー 薬物療法学養生法において感覚的な条件付け手がかり（ｓｅｎｓｏｒｙｃｏｎｄｉｔｉｏｎｉｎｇｃｕｅｓ）を付け加える方法
EP2213278A1 (de) * 2009-01-28 2010-08-04 Labtec GmbH Pharmazeutische Zubereitung mit verbesserter Stabilität des Wirkstoffs
WO2010151745A1 (en) * 2009-06-25 2010-12-29 Elite Laboratories, Inc. Oral dosage forms
CN102958515A (zh) 2009-12-02 2013-03-06 阿普塔利斯制药有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
ES2689520T3 (es) 2010-04-23 2018-11-14 Kempharm, Inc. Formulación terapéutica para reducir los efectos secundarios de fármacos
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
WO2013059676A1 (en) 2011-10-21 2013-04-25 Subhash Desai Compositions for reduction of side effects
US10556011B2 (en) 2011-12-02 2020-02-11 Joshua D. Levine Method and system for adding sensory conditioning cues in a pharmacotherapeutic regimen
US20160022591A1 (en) * 2013-03-15 2016-01-28 Mylan Inc. Extended release pharmaceutical solid dosage formulations
PT2838510T (pt) 2013-11-08 2016-11-23 Lilly Co Eli Solução de atomoxetina
GR1008531B (el) * 2014-03-21 2015-07-13 Λαμδα Φαρμακευτικα Εργαστηρια Εφαμροσμενης Ερευνας Και Αναπτυξης Α.Ε., Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη
GB201420311D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
GB201420300D0 (en) * 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Tablet
GB201420306D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
HK1245117A1 (zh) 2014-12-03 2018-08-24 Velicept Therapeutics, Inc. 使用调节释放索拉贝隆用於下尿路症状的组合物和方法
EP3069715A1 (en) * 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
ES2967863T3 (es) 2015-10-23 2024-05-06 B3Ar Therapeutics Inc Ion dipolar de solabegron y usos del mismo
US20170348288A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
JP2018020999A (ja) * 2016-08-05 2018-02-08 高田製薬株式会社 アトモキセチン錠剤およびアトモキセチン錠剤の製造方法
CA3075292A1 (en) * 2017-10-20 2019-04-25 Purdue Pharma L.P. Pharmaceutical dosage forms
WO2020264092A1 (en) * 2019-06-26 2020-12-30 Celista Pharmaceuticals Llc Atomoxetine hydrochloride extended release compositions and methods of use
JP7090847B2 (ja) * 2020-12-01 2022-06-27 高田製薬株式会社 アトモキセチン錠剤およびアトモキセチン錠剤の製造方法
EP4304565A1 (en) * 2021-03-09 2024-01-17 Tulex Pharmaceuticals, Inc. Extended-release compositions comprising atomoxetine
AU2023365355A1 (en) * 2022-10-19 2025-05-29 Vitakey Inc. Formulated food products
WO2025067690A1 (en) * 2023-09-29 2025-04-03 Roquette Freres Use of a stearic acid salt for improving the surface of sugar-coated solid forms

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
US4797286A (en) * 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4847092A (en) * 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US4868344A (en) * 1988-03-30 1989-09-19 Aldrich-Boranes, Inc. Novel process of producing phenyl or substituted phenylalkylamine pharmaceutical agents and novel chiral intermediates of high enantiomeric purity useful therein
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US5356812A (en) * 1990-08-10 1994-10-18 Daicel Chemical Industries, Ltd. Processes for production of optically active 3-phenyl-1,3-propanediol by asymmetric assimilation
DK0492497T3 (da) * 1990-12-24 1997-01-06 Hoechst Ag Fremgangsmåde til acylering af alkoholer med en immobiliseret pseudomonas-lipase
CA2061665C (en) * 1991-02-25 2002-04-16 Mark Mortensen Foreman Treatment of lower urinary tract disorders
EP0518263A1 (en) * 1991-06-10 1992-12-16 Hoechst-Roussel Pharmaceuticals Incorporated Micropellets and a process for their manufacture
US5328697A (en) * 1992-02-10 1994-07-12 Mallinckrodt Veterinary, Inc. Compositions and processes for the sustained release of drugs
US5395983A (en) * 1992-07-23 1995-03-07 Chisso Corporation Process for producing 1-phenyl-1,3-propanediols having high optical purtiy
US6162949A (en) * 1994-12-16 2000-12-19 Uop Llc Process for preparation of the pharmaceutically desired (S)-oxetine enantiomers
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
CA2277220A1 (en) * 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
JP4344405B2 (ja) * 1997-08-26 2009-10-14 アベンティス・ファーマスーティカルズ・インコーポレイテッド ピペリジノアルカノール−鬱血除去剤の組合せ用医薬組成物
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
EP1017372A4 (en) * 1997-10-03 2006-05-24 Smithkline Beecham Corp SOLID GALENIC FORMS WITH CONTROLLED LITHIUM CARBONATE RELEASE
ZA989251B (en) * 1997-10-17 2000-04-10 Lilly Co Eli Potentiation of pharmaceuticals.
US6245782B1 (en) * 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
ITMI991316A1 (it) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
JP2005501070A (ja) * 2001-08-08 2005-01-13 イーライ・リリー・アンド・カンパニー 神経障害を処置するための組み合わせ療法
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
EP1715856B1 (en) 2012-07-11
JP2007517050A (ja) 2007-06-28
EP1715856A1 (en) 2006-11-02
CA2552064A1 (en) 2005-07-21
US20050152974A1 (en) 2005-07-14
WO2005065673A1 (en) 2005-07-21
AU2004312059A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
ES2390879T3 (es) Formulaciones de atomoxetina
ES2395119T3 (es) Composiciones farmacéuticas de aripiprazol
US20050158383A1 (en) Quetiapine formulations
US20050232990A1 (en) Donepezil formulations
US20050163858A1 (en) Ziprasidone formulations
EP1763337A2 (en) Immediate, controlled and sustained release formulations of galanthamine
US20050163842A1 (en) Rosiglitazone and metformin formulations
US20050163837A1 (en) Rosiglitazone formulations
WO2008070072A2 (en) Carvedilol forms, compositions, and methods of preparation thereof
US20050163843A1 (en) Alprazolam formulations
US20060263427A1 (en) Quinine formulations
JP2010523640A (ja) 医薬組成物
US20060039975A1 (en) Paroxetine formulations
ES3060119T3 (en) Pharmaceutical composition comprising eliglustat